Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PredilifeFRA:0GA -22.85%35 Cyclically Adjusted PS Ratio is 14.44 as of Jul. 20, 2026, which is 58% below its 10-year median of 34.44. GuruFocus rates FRA:0GA with a GF Score™ of 35/100 and a GF Value™ of €19.52 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 136 Medical Diagnostics & Research companies, Predilife ranks worse than 91.91% on this metric.
The historical rank and industry rank for Predilife's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:0GA'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.16 Med: 34.44 Max: 37
Current: 14.16
During the past 10 years, Predilife's highest Cyclically Adjusted PS Ratio was 37.00. The lowest was 14.16. And the median was 34.44.
FRA:0GA's Cyclically Adjusted PS Ratio is ranked worse than 91.91% of 136
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.885
vs FRA:0GA: 14.16
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Predilife's adjusted revenue per share data of for the fiscal year that ended in Dec25 was €0.297. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.09 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Predilife (FRA:0GA) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Predilife Cyclically Adjusted PS Ratio Related Terms
Predilife Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Predilife's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0GA vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison
For the Diagnostics & Research subindustry, Predilife's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predilife Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Predilife's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Predilife's Cyclically Adjusted PS Ratio falls into.
Predilife Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Predilife's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 14.44 mean?
Predilife (FRA:0GA) has a Cyclically Adjusted PS Ratio of 14.44 as of Jul. 20, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Predilife and its competitors. This is 58% below median its historical median of 34.44. Over the past decade, Predilife's Cyclically Adjusted PS Ratio has ranged from 14.16 to 37.00. According to the industry distribution chart, Predilife ranks #125 out of 136 companies in the Medical Diagnostics & Research industry, placing it in the top 91.9%.
Is Predilife's Cyclically Adjusted PS Ratio too high?
Predilife's current Cyclically Adjusted PS Ratio of 14.44 is 58% below median its 10-year median of 34.44. Over the past 10 years, this metric has ranged from a low of 14.16 to a high of 37.00. The Medical Diagnostics & Research industry median Cyclically Adjusted PS Ratio is 1.89. Predilife's value of 14.44 is 666% above this industry median. Based on the distribution chart, Predilife ranks #125 out of 136 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Predilife has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Predilife's Cyclically Adjusted PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Predilife ranks #125 out of 136 companies for Cyclically Adjusted PS Ratio. This places Predilife in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.89. Predilife's value of 14.44 is 666% above this benchmark. Historically, Predilife's own Cyclically Adjusted PS Ratio has ranged from 14.16 to 37.00 over the past decade. While the company's 10-year median is 34.44 vs. the industry median of 1.89, Predilife has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PS Ratio among Medical Diagnostics & Research companies is 1.89, based on 136 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Predilife's current Cyclically Adjusted PS Ratio of 14.44 is 666% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Predilife and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PS Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Predilife's current Cyclically Adjusted PS Ratio is 14.44, which is 58% below median its own 10-year median of 34.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Predilife stock overvalued right now?
Based on GuruFocus' analysis, Predilife (FRA:0GA) is currently considered Possible Value Trap. The stock's GF Value™ is €19.52, compared to a current price of €1.30 — trading 93.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 14.44, which is 58% below median its 10-year median of 34.44 and 666% above the Medical Diagnostics & Research industry median of 1.89. Predilife's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Predilife (FRA:0GA), the current Cyclically Adjusted PS Ratio is 14.44 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Predilife (FRA:0GA) Overvalued in 2026?
Based on GuruFocus' analysis, Predilife stock appears to be undervalued.
The current stock price of €1.30 is trading 93.3% below its estimated GF Value™ of €19.52.
GuruFocus considers Predilife to be Possible Value Trap.
Key valuation signals for FRA:0GA:
Cyclically Adjusted PS Ratio: 14.44 (58% below median its 10-year median of 34.44)
GF Value™: €19.52 vs. price of €1.30 (93.3% below fair value)
Industry Position: 666% above the Medical Diagnostics & Research median (#125 of 136)
No single metric tells the full story. See the FRA:0GA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Predilife SA develops solutions for predictive medicine, combining medical techniques (genetic tests, medical imaging) and mathematical models with a large amount of statistical data, which allows each individual to define their risk profile for the occurrence of various serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.
35GF Score
Get the complete analysis for FRA:0GA
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0GA has been successfully added to your 
